(Total Views: 750)
Posted On: 06/25/2020 12:53:15 PM
Post# of 110
HOTTEST Covid 19 Gem
Low valuation of 48 million / 3x Phase 3 programs with Data in Q4 / Covid 19 Vaccine data soon ..has potential to move like INO or NVAX ...STRONG BUY
Presentation
http://ir.soligenix.com/download/Soligenix+Co...0FINAL.pdf
SNGX: Q&A on COVID-19 Vaccine Candidate CiVax™…
https://finance.yahoo.com/news/sngx-q-covid-1...00828.html
As a reminder, following the positive topline data presented by the company for SGX-301 in CTCL, we continue to anticipate Phase 3 data for SGX-942 in oral mucositis in the fourth quarter of 2020. The company will also be joining the Russell Microcap Index effective June 29th, 2020, which should help to increase visibility within the investment community. Our current valuation is $12 per share.
Low valuation of 48 million / 3x Phase 3 programs with Data in Q4 / Covid 19 Vaccine data soon ..has potential to move like INO or NVAX ...STRONG BUY
Presentation
http://ir.soligenix.com/download/Soligenix+Co...0FINAL.pdf
SNGX: Q&A on COVID-19 Vaccine Candidate CiVax™…
https://finance.yahoo.com/news/sngx-q-covid-1...00828.html
As a reminder, following the positive topline data presented by the company for SGX-301 in CTCL, we continue to anticipate Phase 3 data for SGX-942 in oral mucositis in the fourth quarter of 2020. The company will also be joining the Russell Microcap Index effective June 29th, 2020, which should help to increase visibility within the investment community. Our current valuation is $12 per share.
(0)
(0)
